Published in Cell Res on April 20, 2010
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell (2012) 3.10
The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol (2012) 1.82
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol (2013) 1.66
Dynamics of B cells in germinal centres. Nat Rev Immunol (2015) 1.61
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell (2012) 1.40
Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. Mol Cell Biol (2010) 1.24
Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. Nat Rev Immunol (2013) 1.18
Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med (2014) 1.12
Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1. J Immunol (2011) 0.97
Lymphocyte lineage-specific and developmental stage specific mechanisms suppress cyclin D3 expression in response to DNA double strand breaks. Cell Cycle (2016) 0.85
Translational repression of cyclin D3 by a stable G-quadruplex in its 5' UTR: implications for cell cycle regulation. RNA Biol (2012) 0.84
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res (2014) 0.84
Increased expression of PcG protein YY1 negatively regulates B cell development while allowing accumulation of myeloid cells and LT-HSC cells. PLoS One (2012) 0.81
Viral cyclins mediate separate phases of infection by integrating functions of distinct mammalian cyclins. PLoS Pathog (2012) 0.81
Substituting threonine 187 with alanine in p27Kip1 prevents pituitary tumorigenesis by two-hit loss of Rb1 and enhances humoral immunity in old age. J Biol Chem (2015) 0.80
Cyclin D3 critically regulates the balance between self-renewal and differentiation in skeletal muscle stem cells. Stem Cells (2013) 0.80
Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice. Leukemia (2015) 0.78
Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus. Cell Mol Immunol (2015) 0.78
BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy. Oncotarget (2016) 0.76
Role of MYC in B Cell Lymphomagenesis. Genes (Basel) (2017) 0.75
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science (2009) 9.22
Bcl6 mediates the development of T follicular helper cells. Science (2009) 8.50
The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity (2009) 7.69
Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science (1997) 6.58
Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol (2008) 6.09
Mechanism and regulation of class switch recombination. Annu Rev Immunol (2008) 5.98
G1 cell-cycle control and cancer. Nature (2004) 5.72
Germinal-center organization and cellular dynamics. Immunity (2007) 5.62
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity (2000) 5.36
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86
The biochemistry of somatic hypermutation. Annu Rev Immunol (2008) 3.78
Signatures of the immune response. Immunity (2001) 3.66
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene (2009) 3.51
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
B cell receptor signal strength determines B cell fate. Nat Immunol (2004) 3.06
In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J Exp Med (1998) 3.04
Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A (2006) 2.83
Evidence of marginal-zone B cell-positive selection in spleen. Immunity (2005) 2.41
Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med (1996) 2.18
Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. Nat Immunol (2004) 2.16
CD19 regulates B cell maturation, proliferation, and positive selection in the FDC zone of murine splenic germinal centers. Immunity (2005) 2.10
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood (2009) 2.04
B cell intrinsic TLR signals amplify but are not required for humoral immunity. J Exp Med (2007) 1.89
Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest (2003) 1.63
Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol (2006) 1.62
A unique function for cyclin D3 in early B cell development. Nat Immunol (2006) 1.51
Ras orchestrates exit from the cell cycle and light-chain recombination during early B cell development. Nat Immunol (2009) 1.48
CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol (2008) 1.41
Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem (2000) 1.39
Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood (2001) 1.36
Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle (2005) 1.35
Divide and conquer: the importance of cell division in regulating B-cell responses. Immunology (2004) 1.31
The physiologic role of CD19 cytoplasmic tyrosines. Immunity (2002) 1.25
Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J Exp Med (2009) 1.25
BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 production. Blood (2004) 1.20
CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity (2002) 1.18
Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol (1998) 1.13
The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol (2005) 1.08
Distinct proliferative and transcriptional effects of the D-type cyclins in vivo. Cell Cycle (2008) 1.03
The human CD77- B cell population represents a heterogeneous subset of cells comprising centroblasts, centrocytes, and plasmablasts, prompting phenotypical revision. J Immunol (2006) 1.02
Expression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer (1999) 0.98
Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res (2002) 0.95
Disruption of cyclin D3 blocks proliferation of normal B-1a cells, but loss of cyclin D3 is compensated by cyclin D2 in cyclin D3-deficient mice. J Immunol (2006) 0.88
Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene (2007) 0.84
Cyclin E ablation in the mouse. Cell (2003) 5.58
Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 5.50
Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci U S A (2003) 4.89
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86
The biochemistry of somatic hypermutation. Annu Rev Immunol (2008) 3.78
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol (2005) 3.50
Cognition and immunity; antibody impairs memory. Immunity (2004) 3.40
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.05
Kinase-independent function of cyclin E. Mol Cell (2007) 3.03
TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol (2008) 3.02
Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A (2006) 2.97
Requirement for CDK4 kinase function in breast cancer. Cancer Cell (2006) 2.92
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell (2006) 2.91
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood (2008) 2.85
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature (2011) 2.82
Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A (2006) 2.51
The requirement for cyclin D function in tumor maintenance. Cancer Cell (2012) 2.49
Development of mice expressing a single D-type cyclin. Genes Dev (2002) 2.43
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell (2011) 2.41
On the track of neuropsychiatric lupus. Arthritis Rheum (2003) 2.39
Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature (2002) 2.35
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood (2007) 2.28
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med (2009) 2.27
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood (2008) 2.24
Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature (2010) 2.20
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell (2012) 2.18
Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. Nat Immunol (2004) 2.16
Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1. Nat Immunol (2007) 2.15
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood (2010) 2.11
Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells. Cell (2009) 2.05
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood (2009) 2.04
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum (2008) 2.00
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood (2012) 1.98
Female mouse fetal loss mediated by maternal autoantibody. J Exp Med (2012) 1.92
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (2013) 1.91
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Cyclin E constrains Cdk5 activity to regulate synaptic plasticity and memory formation. Dev Cell (2011) 1.89
Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum (2006) 1.87
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81
The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev (2004) 1.76
Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest (2002) 1.76
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood (2007) 1.72
Somatic hypermutation of the AID transgene in B and non-B cells. Proc Natl Acad Sci U S A (2002) 1.71
XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med (2009) 1.71
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
The retinoblastoma protein regulates pericentric heterochromatin. Mol Cell Biol (2006) 1.68
Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc Natl Acad Sci U S A (2011) 1.66
Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A (2010) 1.65
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol (2006) 1.62
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med (2010) 1.56
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
AID and mismatch repair in antibody diversification. Nat Rev Immunol (2002) 1.55
Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med (2008) 1.54
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol (2004) 1.53
A unique function for cyclin D3 in early B cell development. Nat Immunol (2006) 1.51
Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet (2013) 1.50
Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. Hepatology (2013) 1.48
Detection of chromatin-associated single-stranded DNA in regions targeted for somatic hypermutation. J Exp Med (2007) 1.46
Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood (2006) 1.46
Methylation protects cytidines from AID-mediated deamination. Mol Immunol (2005) 1.46
B cell selection and susceptibility to autoimmunity. J Immunol (2005) 1.46
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol (2009) 1.46
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med (2011) 1.45
Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One (2008) 1.45
The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One (2010) 1.42
CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol (2008) 1.41
Examination of Msh6- and Msh3-deficient mice in class switching reveals overlapping and distinct roles of MutS homologues in antibody diversification. J Exp Med (2004) 1.41
Canonical and atypical E2Fs regulate the mammalian endocycle. Nat Cell Biol (2012) 1.37
Identification of an antigen-specific B cell population. J Immunol Methods (2003) 1.36
Induction of somatic hypermutation is associated with modifications in immunoglobulin variable region chromatin. Immunity (2003) 1.35
Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle (2005) 1.35
Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol (2004) 1.35
Msh2 ATPase activity is essential for somatic hypermutation at a-T basepairs and for efficient class switch recombination. J Exp Med (2003) 1.33
HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med (2012) 1.33
Ubiquitylated PCNA plays a role in somatic hypermutation and class-switch recombination and is required for meiotic progression. Proc Natl Acad Sci U S A (2008) 1.32
Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci U S A (2002) 1.30
The critical role of cyclin D2 in adult neurogenesis. J Cell Biol (2004) 1.30
Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med (2011) 1.29
SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood (2011) 1.29
Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle (2006) 1.28
PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. J Pathol (2005) 1.27
Tolerogenic function of Blimp-1 in dendritic cells. J Exp Med (2011) 1.26
ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol (2007) 1.25
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun (2002) 1.24
The RNF8/RNF168 ubiquitin ligase cascade facilitates class switch recombination. Proc Natl Acad Sci U S A (2009) 1.24